JO Volume 5 - Hepatitis - Clinical Care Options

Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors: Bacon BR, Gordon SC, Lawitz E, et al.

Citation: N Engl J Med. 2011;364:1207-1217.

Source: Journal Options for Hepatitis - Volume 5

Date Posted: 12/9/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
The cost-effectiveness of screening for chronic hepatitis B infection in the United States.

Authors: Eckman MH, Kaiser TE, Sherman KE.

Citation: Clin Infect Dis. 2011;52:1294-1306.

Source: Journal Options for Hepatitis - Volume 5

Date Posted: 12/9/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

Authors: Foster GR, Hézode C, Bronowicki JP, et al.

Citation: Gastroenterology. 2011;141:881-889.

Source: Journal Options for Hepatitis - Volume 5

Date Posted: 12/9/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.

Authors: Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X.

Citation: Hepatology. 2011;54:20-27.

Source: Journal Options for Hepatitis - Volume 5

Date Posted: 12/9/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors: Jacobson IM, McHutchison JG, Dusheiko G, et al.

Citation: N Engl J Med. 2011;364:2405-2416.

Source: Journal Options for Hepatitis - Volume 5

Date Posted: 12/9/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Boceprevir for untreated chronic HCV genotype 1 infection.

Authors: Poordad F, McCone J Jr, Bacon BR, et al.

Citation: N Engl J Med. 2011;364:1195-1206.

Source: Journal Options for Hepatitis - Volume 5

Date Posted: 12/9/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Response-guided telaprevir combination treatment for hepatitis C virus infection.

Authors: Sherman KE, Flamm SL, Afdhal NH, et al.

Citation: N Engl J Med. 2011;365:1014-1024.

Source: Journal Options for Hepatitis - Volume 5

Date Posted: 12/9/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Telaprevir for retreatment of HCV infection.

Authors: Zeuzem S, Andreone P, Pol S, et al.

Citation: N Engl J Med. 2011;364:2417-2428.

Source: Journal Options for Hepatitis - Volume 5

Date Posted: 12/9/2011

Capsule Summary | Expert Commentary | Slideset | Abstract

Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.

Other Sites

Topics

Educational Formats

Program Resources

User Resources

Video

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Journal Options for Hepatitis - Volume 5 Source: Journal Options for Hepatitis - Volume 5
Table of Contents Issue 1 Collection • Issue 1 Collection Articles	Latest Content 8 of 8 Shown Boceprevir for previously treated chronic HCV genotype 1 infection. Authors: Bacon BR, Gordon SC, Lawitz E, et al. Citation: N Engl J Med. 2011;364:1207-1217. Source: Journal Options for Hepatitis - Volume 5 Date Posted: 12/9/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Authors: Eckman MH, Kaiser TE, Sherman KE. Citation: Clin Infect Dis. 2011;52:1294-1306. Source: Journal Options for Hepatitis - Volume 5 Date Posted: 12/9/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Authors: Foster GR, Hézode C, Bronowicki JP, et al. Citation: Gastroenterology. 2011;141:881-889. Source: Journal Options for Hepatitis - Volume 5 Date Posted: 12/9/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Authors: Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Citation: Hepatology. 2011;54:20-27. Source: Journal Options for Hepatitis - Volume 5 Date Posted: 12/9/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Telaprevir for previously untreated chronic hepatitis C virus infection. Authors: Jacobson IM, McHutchison JG, Dusheiko G, et al. Citation: N Engl J Med. 2011;364:2405-2416. Source: Journal Options for Hepatitis - Volume 5 Date Posted: 12/9/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Boceprevir for untreated chronic HCV genotype 1 infection. Authors: Poordad F, McCone J Jr, Bacon BR, et al. Citation: N Engl J Med. 2011;364:1195-1206. Source: Journal Options for Hepatitis - Volume 5 Date Posted: 12/9/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Response-guided telaprevir combination treatment for hepatitis C virus infection. Authors: Sherman KE, Flamm SL, Afdhal NH, et al. Citation: N Engl J Med. 2011;365:1014-1024. Source: Journal Options for Hepatitis - Volume 5 Date Posted: 12/9/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Telaprevir for retreatment of HCV infection. Authors: Zeuzem S, Andreone P, Pol S, et al. Citation: N Engl J Med. 2011;364:2417-2428. Source: Journal Options for Hepatitis - Volume 5 Date Posted: 12/9/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract 8 of 8 Shown Show 0 More Loading...	Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. Contact Info Educational grant provided by: Educational grants support only the CME-certified components of this program.

Source: Journal Options for Hepatitis - Volume 5

Table of Contents

Latest Content